<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Exelixis Inc — News on 6ix</title>
<link>https://6ix.com/company/exelixis-inc</link>
<description>Latest news and press releases for Exelixis Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/exelixis-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835659678dffbe2df0f0244.webp</url>
<title>Exelixis Inc</title>
<link>https://6ix.com/company/exelixis-inc</link>
</image>
<item>
<title>Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-to-release-first-quarter-2026-financial-results-on-tuesday-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-to-release-first-quarter-2026-financial-results-on-tuesday-may-5-2026</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>ALAMEDA, Calif., April 21, 2026--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.</description>
</item>
<item>
<title>Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-march</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-march</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>ALAMEDA, Calif., February 24, 2026--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March:</description>
</item>
<item>
<title>Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-announces-fourth-quarter-fiscal-210500794</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-announces-fourth-quarter-fiscal-210500794</guid>
<pubDate>Tue, 10 Feb 2026 21:05:00 GMT</pubDate>
<description>ALAMEDA, Calif., February 10, 2026--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.</description>
</item>
<item>
<title>Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-announces-us-fda-accepted-new-drug-application-zanzalintinib-combination</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-announces-us-fda-accepted-new-drug-application-zanzalintinib-combination</guid>
<pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
<description>– The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 – – Application is based on results from the phase 3 STELLAR-303</description>
</item>
<item>
<title>Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-release-fourth-quarter-fiscal-210500559</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-release-fourth-quarter-fiscal-210500559</guid>
<pubDate>Tue, 27 Jan 2026 21:05:00 GMT</pubDate>
<description>ALAMEDA, Calif., January 27, 2026--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.</description>
</item>
<item>
<title>Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-announces-preliminary-fiscal-year-2025-financial-results-provides-2026</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-announces-preliminary-fiscal-year-2025-financial-results-provides-2026</guid>
<pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
<description>– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product</description>
</item>
<item>
<title>Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-and-natera-collaborate-stellar-316-phase-3-pivotal-trial-zanzalintinib-1</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-and-natera-collaborate-stellar-316-phase-3-pivotal-trial-zanzalintinib-1</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy – ALAMEDA, Calif.</description>
</item>
<item>
<title>Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-present-jp-morgan-2026-healthcare-conference-january-12-2026-2026-01-06</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-present-jp-morgan-2026-healthcare-conference-january-12-2026-2026-01-06</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>– Presentation to be webcast on www.exelixis.com – ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M.</description>
</item>
<item>
<title>Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-webcast-virtual-2025-research-development-rd-day-wednesday-december-10-2025</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-webcast-virtual-2025-research-development-rd-day-wednesday-december-10-2025</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>- Event to Review R&D Progress and Outline Exelixis’ Strategy for Building Next-generation Oncology Franchises - ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis,</description>
</item>
<item>
<title>Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-webcast-fireside-chats-part-upcoming-investor-conferences-november-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-webcast-fireside-chats-part-upcoming-investor-conferences-november-2025-11</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management</description>
</item>
<item>
<title>Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-announces-third-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-announces-third-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of</description>
</item>
<item>
<title>Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-release-third-quarter-2025-financial-results-tuesday-november-4-2025-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-release-third-quarter-2025-financial-results-tuesday-november-4-2025-2025-10</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) announced today</description>
</item>
<item>
<title>Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-announces-detailed-results-phase-3-stellar-303-pivotal-trial-evaluating</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-announces-detailed-results-phase-3-stellar-303-pivotal-trial-evaluating</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly</description>
</item>
<item>
<title>Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-announces-results-subgroup-analysis-cabinet-phase-3-pivotal-trial-evaluating</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-announces-results-subgroup-analysis-cabinet-phase-3-pivotal-trial-evaluating</guid>
<pubDate>Sat, 18 Oct 2025 04:00:00 GMT</pubDate>
<description>– CABOMETYX reduced the risk of disease progression or death by 81% versus placebo in patients with advanced lung or thymic neuroendocrine tumors (NET) – –</description>
</item>
<item>
<title>Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate</title>
<link>https://6ix.com/company/exelixis-inc/news/adagene-expands-safebodyr-collaboration-and-license-agreement-with-exelixis-to-develop-third-novel-masked-antibody-drug-conjugate</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/adagene-expands-safebodyr-collaboration-and-license-agreement-with-exelixis-to-develop-third-novel-masked-antibody-drug-conjugate</guid>
<pubDate>Tue, 16 Sep 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will utilize Adagene’s SAFEbody technology platform to generate a masked monoclonal antibody from the company’s pipeline for the development of an antibody-drug conjugate (ADC) against an Exelixis-nominated solid tumor target. Adagene is eligible to rec</description>
</item>
<item>
<title>Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-announces-appointment-dana-t-aftab-phd-executive-vice-president-research-and</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-announces-appointment-dana-t-aftab-phd-executive-vice-president-research-and</guid>
<pubDate>Fri, 29 Aug 2025 04:00:00 GMT</pubDate>
<description>– Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company’s scientific innovation and development activities –</description>
</item>
<item>
<title>Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-webcast-fireside-chats-part-upcoming-investor-conferences-september-2025-08</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-webcast-fireside-chats-part-upcoming-investor-conferences-september-2025-08</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management</description>
</item>
<item>
<title>Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-announces-second-quarter-2025-financial-results-and-provides-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-announces-second-quarter-2025-financial-results-and-provides-corporate</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>- Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 million - - GAAP Diluted EPS of $0.65, Non-GAAP Diluted EPS of</description>
</item>
<item>
<title>Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-partner-ipsen-receives-european-commission-approval-cabometyxr-cabozantinib</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-partner-ipsen-receives-european-commission-approval-cabometyxr-cabozantinib</guid>
<pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
<description>– Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement</description>
</item>
<item>
<title>Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025</title>
<link>https://6ix.com/company/exelixis-inc/news/exelixis-release-second-quarter-2025-financial-results-monday-july-28-2025-2025-07-14</link>
<guid isPermaLink="true">https://6ix.com/company/exelixis-inc/news/exelixis-release-second-quarter-2025-financial-results-monday-july-28-2025-2025-07-14</guid>
<pubDate>Mon, 14 Jul 2025 04:00:00 GMT</pubDate>
<description>– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) announced today</description>
</item>
</channel>
</rss>